Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Sep 5;14(1):152.
doi: 10.1038/s41408-024-01134-3.

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

Ricardo D Parrondo  1 , Betsy R LaPlant  2 , Jamie Elliott  1 , Andre Fernandez  1 , Caitlin J Flott  1 , Diedre Arrington  1 , Dustin Chapin  1 , Jade Brown  1 , Saurav Das  1 , Vivek Roy  1 , Asher A Chanan-Khan  1   3 , Sikander Ailawadhi  4   5
Affiliations
Clinical Trial

Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

Ricardo D Parrondo et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

BRL, JE, AF, CJF, DA, DC, JB, SD and VR have no conflicts of interest to declare. RDP serves on the advisory board for Sanofi Aventis and Astra Zeneca and has received research funding from Bristol Myers Squibb Foundation and GlaxoSmithKline. SA has provided consultancy for Celgene, Amgen, Janssen and Takeda, and has received research funding from Pharmacyclics, Cellectar and Janssen. AAC-K has received research funding from Xencor Pharmacyclics, Merck, Janssen, Ascentage and Millennium.

Figures

Fig. 1
Fig. 1. Survival outcomes.
A PFS and OS of study population. B PFS and OS of study population based on triple-class refractory status.
See this image and copyright information in PMC

References

    1. Joseph NS, Kaufman JL, Dicamillo S, Roberts D, Gupta VA, Hofmeister CC, et al. Comparison of response and survival outcomes in standard- and high-risk newly diagnosed transplant-eligible multiple myeloma (NDMM) patients treated with lenalidomide, bortezomib and dexamethasone (RVD) versus daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD). Blood. 2023;142:647.10.1182/blood-2023-187339 - DOI
    1. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62:1841–9. 10.1007/s00262-013-1493-8 - DOI - PMC - PubMed
    1. Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10:91. 10.1038/s41408-020-00357-4 - DOI - PMC - PubMed
    1. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–31. 10.1056/NEJMoa1505654 - DOI - PubMed
    1. Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811–22. 10.1056/NEJMoa1805762 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources